Abstract
Conventional antipsychotic agents are not effective against negative symptoms of schizophrenia and are also noted for their extrapyramidal side effects. Risperidone is a noval antipsychotic agent whose dual antagonism of dopamine and serotonin receptors is believed to underlie its efficacy against negative symptoms and the low incidence of extrapyramidal side effects. An open, non-comparative study of seven weeks duration was performed to evaluate risperidone in the treatment of schizophrenia in Indian patients. Previous antipsychotic therapy was discontinued for a week before risperidone therapy was initiated. At the end of six weeks of risperidone therapy, clinical improvement (≥ 20% reduction in total score on positive and negative syndrome scale for schizophrenia (PANSS;; was shown by 128 (87.7%) of the 146 evaluable patients. Statistically significant reduction (p < 0.05) occurred in the total score of this scale and in the subscale scores for positive, negative and general psychopathology symptoms and in the clinical global impression severity score. The number of patients with adverse experiences were 108 (65.5%) at baseline and 120 (72.7%) at the end of risperidone therapy. Extrapyramidal symptoms, seen in 65 (39.4%) patients compared to 22 (13.3%) patients at baseline, were largely mild to moderate in intensity.
Keywords: Risperidone, novel antipsychotic agents, Indian patients, schizophrenia, PANSS, clinical improvement
Full Text
The Full Text of this article is available as a PDF (283.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol. 1990 Dec;13(6):500–506. doi: 10.1097/00002826-199012000-00003. [DOI] [PubMed] [Google Scholar]
- Bleich A., Brown S. L., Kahn R., van Praag H. M. The role of serotonin in schizophrenia. Schizophr Bull. 1988;14(2):297–315. doi: 10.1093/schbul/14.2.297. [DOI] [PubMed] [Google Scholar]
- Borison R. L., Pathiraja A. P., Diamond B. I., Meibach R. C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992;28(2):213–218. [PubMed] [Google Scholar]
- Cesková E., Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993 Jul;26(4):121–124. [PubMed] [Google Scholar]
- Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
- Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 Apr;85(4):295–305. doi: 10.1111/j.1600-0447.1992.tb01473.x. [DOI] [PubMed] [Google Scholar]
- Davis J. M., Janicak P. G. Efficacy and safety of the new antipsychotics. Lancet. 1994 Feb 19;343(8895):476–477. [PubMed] [Google Scholar]
- Gelders Y. G., Heylen S. L., Vanden Bussche G., Reyntjens A. J., Janssen P. A. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry. 1990 Sep;23(5):206–211. doi: 10.1055/s-2007-1014509. [DOI] [PubMed] [Google Scholar]
- Høyberg O. J., Fensbo C., Remvig J., Lingjaerde O., Sloth-Nielsen M., Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395–402. doi: 10.1111/j.1600-0447.1993.tb03480.x. [DOI] [PubMed] [Google Scholar]
- Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988 Sep;45(9):789–796. doi: 10.1001/archpsyc.1988.01800330013001. [DOI] [PubMed] [Google Scholar]
- Leysen J. E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J. C., Janssen P. A. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988 Nov;247(2):661–670. [PubMed] [Google Scholar]
- Leysen J. E., Gommeren W., Eens A., de Chaffoy de Courcelles D., Stoof J. C., Janssen P. A. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988 Nov;247(2):661–670. [PubMed] [Google Scholar]
- Marder S. R. Clinical experience with risperidone. J Clin Psychiatry. 1996;57 (Suppl 9):57–61. [PubMed] [Google Scholar]
- Marder S. R., Meibach R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. doi: 10.1176/ajp.151.6.825. [DOI] [PubMed] [Google Scholar]
- Megens A. A., Awouters F. H., Niemegeers C. J. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol. Psychopharmacology (Berl) 1988;95(4):493–496. doi: 10.1007/BF00172961. [DOI] [PubMed] [Google Scholar]
- Müller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group. Clin Neuropharmacol. 1992;15 (Suppl 1 Pt A):90A–91A. doi: 10.1097/00002826-199201001-00048. [DOI] [PubMed] [Google Scholar]
- Roose K., Gelders Y., Heylen S. Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration. Acta Psychiatr Belg. 1988 May-Jun;88(3):233–241. [PubMed] [Google Scholar]